Cancer:乳腺癌保乳术后加速部分乳房照射和辅助放疗

2016-09-30 MedSci MedSci原创

加速部分乳房照射的初步研究提示在选择性的早期乳腺癌患者中局部控制率可以与接受标准的全乳放疗治疗者相比较。但是,与标准的全乳照射相比,最近一些研究证明加速部分乳房照射美容结果较差。根据美国放射肿瘤学会(ASTRO)的共识声明,可能适于加速部分乳房照射的患者是≥60岁、非BRCA 1/2突变的携带者者、单病灶T1N0 ER阳性肿瘤初次手术治疗的女性。组织学应该是浸润性导管或一种良好的导管亚型并且没有广

当前研究的目的是确定加速部分乳房照射(APBI)与辅助性放射治疗(RT)的使用是否存在差异。

根据国家的癌症数据,研究人员对年龄≥50岁,2004-2013年间被诊断出患有早期乳腺癌并接受保乳手术(BCS)的女性患者进行了回顾性研究。≥10%的符合条件的患者接受过APBI治疗,被定义为APBI组;而未进行APBI治疗的被定义为定义为非APBI组。其他设施的治疗都被排除在外。研究人员通过对整体样本的多变量逻辑回归分析确定与辅助放疗相关的独立因素,并在标准风险的浸润性癌、低风险的浸润性癌和原位管癌的患者亚群分析。

结果显示,222544例患者中,76.6%的曾接受过BCS + RT治疗,剩下的23.4%只接受过BCS治疗。在APBI组和非APBI组,RT在总体样本中被采用的可能性并没有显著不同于(调整后的比值比[AOR],1.02;P =0.61)。多变量分析表明,标准风险的浸润性癌患者中,接受APBI治疗与RT治疗间没有联系(AOR,0.98;P = 0.69)。然而,低风险的浸润性癌症患者会更多接受RT(54.4% vs 59.5%;AOR,1.22 [ P <0.001]),而原位管癌的患者较少接受RT(56.9% vs 55.3%;P = 0.89 AOR,[ P = 0.04 ])。

结论:该研究中的患者更多曾接受过辅助放疗,但可能从RT治疗中获得最大收益的标准风险的浸润性癌患者似乎并没有什么不同。

注:加速部分乳房照射的初步研究提示在选择性的早期乳腺癌患者中局部控制率可以与接受标准的全乳放疗治疗者相比较。但是,与标准的全乳照射相比,最近一些研究证明加速部分乳房照射美容结果较差。

根据美国放射肿瘤学会(ASTRO)的共识声明,可能适于加速部分乳房照射的患者是≥60岁、非BRCA 1/2突变的携带者者、单病灶T1N0 ER阳性肿瘤初次手术治疗的女性。组织学应该是浸润性导管或一种良好的导管亚型并且没有广泛的导管内癌成分或小叶原位癌以及边缘应该是阴性的。

原始出处:

Wang EH, Park HS,et al.Association between access to accelerated partial breast irradiation and use of adjuvant radiotherapy.Cancer. 2016 Sep 22. doi: 10.1002/cncr.30356. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=154489, encodeId=51b81544894c, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Wed Nov 09 07:25:11 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143101, encodeId=a2ff14310128, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:59:17 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139129, encodeId=471013912948, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:55 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139128, encodeId=5542139128bc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:44 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568306, encodeId=98ff156830682, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Sun Oct 02 14:08:00 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-11-09 镱鉎鉌釚

    真不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=154489, encodeId=51b81544894c, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Wed Nov 09 07:25:11 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143101, encodeId=a2ff14310128, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:59:17 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139129, encodeId=471013912948, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:55 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139128, encodeId=5542139128bc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:44 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568306, encodeId=98ff156830682, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Sun Oct 02 14:08:00 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-10 1e10c84am36(暂无匿称)

    文章很好,继续关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=154489, encodeId=51b81544894c, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Wed Nov 09 07:25:11 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143101, encodeId=a2ff14310128, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:59:17 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139129, encodeId=471013912948, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:55 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139128, encodeId=5542139128bc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:44 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568306, encodeId=98ff156830682, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Sun Oct 02 14:08:00 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-02 doctorJiangchao

    继续学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=154489, encodeId=51b81544894c, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Wed Nov 09 07:25:11 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143101, encodeId=a2ff14310128, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:59:17 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139129, encodeId=471013912948, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:55 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139128, encodeId=5542139128bc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:44 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568306, encodeId=98ff156830682, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Sun Oct 02 14:08:00 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-02 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=154489, encodeId=51b81544894c, content=真不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160903/IMG57CA05C7ADAC62159.jpg, createdBy=ea6c1943408, createdName=镱鉎鉌釚, createdTime=Wed Nov 09 07:25:11 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=143101, encodeId=a2ff14310128, content=文章很好,继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 10 10:59:17 CST 2016, time=2016-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139129, encodeId=471013912948, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:55 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139128, encodeId=5542139128bc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Oct 02 17:53:44 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568306, encodeId=98ff156830682, content=<a href='/topic/show?id=f5d69368591' target=_blank style='color:#2F92EE;'>#辅助放疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93685, encryptionId=f5d69368591, topicName=辅助放疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=135c15357385, createdName=xuyu, createdTime=Sun Oct 02 14:08:00 CST 2016, time=2016-10-02, status=1, ipAttribution=)]
    2016-10-02 xuyu

相关资讯

CSCO 2016:邵志敏教授——中国乳腺癌防治如何突破困境?

2016年,厦门的CSCO大会上,来自复旦大学附属肿瘤医院的邵志敏教授为我们讲述了中国乳腺癌的现状和问题。(邵志敏教授)乳腺癌是女性癌症第一位即使是从世界范围来说,乳腺癌也是位居女性癌症发病之首,全球每年新发乳腺癌病例约167.1万,每年约52.2万患者死于乳腺癌,发达国家乳腺癌发病率相对于欠发达国家更高。(乳腺癌世界地图,上图为发病率地图,下图为死亡率地图。可以看出,发达国家由于早筛等措施到

Cancer:基因测序发现男性乳腺癌的易感基因——PALB2

男性乳腺癌是一种罕见的疾病,只占所有乳腺癌当中的0.6%,而且在所有男性癌症当中占不到1%。遗传因素是男性乳腺癌发生的重要原因。不管是先天因素还是后天因素所导致,雄性激素缺乏、雌性激素分泌过多的男性,都更容易罹患乳腺癌。 与女性乳腺癌比较,男性乳腺癌发现时往往较为晚期,所以肿瘤会比较大,也常伴随有淋巴结的转移。

CSCO 2016:美国乳腺癌防治观念夺人眼球

2016年9月,台风刚过的厦门,CSCO大会如期召开。9月22日上午,美国癌症协会专家Angela DeMichele在CSCO-ASCO Joint Symposium上首先开讲——美国人是怎么搞乳腺癌防治的!讲者:DeMichele教授美国乳腺癌现状到2016年为止,美国乳腺癌患者数量为:246660例女性乳腺癌,为女性癌症的第一位;另有2600例男性乳腺癌。乳腺癌导致的死亡患者数量为40

Cancer:乳腺癌与血统有关,非裔发病率更高

Barbara Haley医生(左)和 Roshni Rao医生。(来源:德州大学西南医学中心)据美国《每日科学》报道,最新研究显示,线粒体基因测试可揭秘血统与特定类型乳腺癌发病率之间的关系。德州大学西南医学中心的癌症研究员通过分析一组三阴性乳腺癌患者的线粒体DNA后发现,有13%的患者并不了解他们的血统对癌症发病率有何影响。本研究第一作者,乳腺外科中心主任Roshni Rao医生说:“我们在92

JCEM:甲功里的这项指标与肺癌、乳腺癌风险有关

体外和体内实验均表明,甲状腺激素中存在抑癌和致癌的成分,但是基于人群的研究却得出不一致的结果。 本项以人群为基础的研究目的是,前瞻性评估甲状腺功能和癌症发生情况之间的关系。 该研究是一项基于人群的前瞻性队列研究,纳入了10318名参与者,基线测量游离甲状腺素(FT4)和/或促甲状腺激素(TSH)。 使用Cox比例风险模型来评估任何非皮肤癌的实体肿瘤风险;以及细分为肺癌、乳腺癌、前

sci Rep:科学家开发出新型乳腺癌检测技术

近日,一项刊登于国际杂志Scientific Reports上的研究报告中,来自澳洲国立大学(Australian National University)的研究人员通过通过与法国的研究者合作开发出了一种有潜力的方法,该方法仅仅通过一种简单的血液检测方法就能够检测并且监测乳腺癌。 相比其它检测手段,比如乳腺癌活组织检查而言,血液检测手段比较便宜而且具有较低的侵入性,乳腺癌是一种常见的